logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
5/17/2022 8:27:11 AM Ultragenyx Buys Global Rights To ABO-102 For Sanfilippo Syndrome Type A (MPS IIIA) From Abeona Therapeutics
5/5/2022 4:56:35 PM Ultragenyx Q1 Loss/share $2.19 Vs. Loss $2.03 Year Ago
2/10/2022 9:27:07 PM Ultragenyx Q4 Loss Widens
2/10/2022 4:40:23 PM Ultragenyx Pharma Q4 Loss/share $1.79 Vs. Loss $0.37 Year Ago
11/29/2021 8:23:54 AM Ultragenyx Reports Addl Positive Multi-Year Durability Data From Phase 1/2 AAV Gene Therapy Studies
11/2/2021 5:17:48 PM Ultragenyx Q3 Loss/share $1.08 Vs. Loss $1.13 Year Ago
8/23/2021 8:33:21 AM Ultragenyx Announces Approval Of Dojolvi In Brazil For Long-chain Fatty Acid Oxidation Disorders In Adults And Children
8/2/2021 4:26:14 PM Ultragenyx Pharma Q2 Loss/share $1.81 Vs. Profit $0.41 Year Ago
7/27/2021 8:49:07 AM Ultragenyx Gets Orphan Drug Designation From FDA And European Commission For UX053 For Glycogen Storage Disease Type III
6/30/2021 8:37:07 AM Ultragenyx Appoints Corsee Sanders To Board Of Directors
6/10/2021 8:48:52 AM Ultragenyx, GeneTx Receive Approval From UK Regulatory Agency To Begin Clinical Study Of GTX-102
5/14/2021 8:37:18 AM Ultragenyx Reports Positive Multi-Year Durability Data From Ongoing Phase 1/2 Gene Therapy Studies
3/8/2021 8:34:18 AM Ultragenyx Announces FDA Clearance Of IND Application For UX053
2/11/2021 4:16:02 PM Ultragenyx Pharma Q4 Loss/share $0.37 Vs. Loss $1.62 Year Ago
1/8/2021 9:05:33 AM Ultragenyx: Durable Response Reported From Phase 1/2 Studies Of DTX401 For GSDIa And DTX301 For OTC